Reaction
Bacterial Vulvovaginitis reporting signals
As of the last recalculation, Bacterial Vulvovaginitis appears in 282 FAERS reports alongside 9 co-occurring drug terms. The strongest observed disproportionality signal is TOFACITINIB CITRATE (PRR 181.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tofacitinib Citrate | 29 | 181.9 | 182.3 |
| Raltegravir | 26 | 127.9 | 128.1 |
| Mercaptopurine | 24 | 111.6 | 111.7 |
| Desoximetasone | 25 | 106.2 | 106.3 |
| Vedolizumab | 37 | 36.3 | 36.4 |
| Copper | 19 | 34.8 | 34.8 |
| Emtricitabine And Tenofovir Disoproxil Fumarate | 16 | 27.4 | 27.4 |
| Ocrelizumab | 20 | 25.5 | 25.6 |
| Levonorgestrel | 30 | 12.2 | 12.2 |